These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 27488429)
1. Reverse Mismatch Pattern in Cardiac 18F-FDG Viability PET/CT Is Not Associated With Poor Outcome of Revascularization: A Retrospective Outcome Study of 91 Patients With Heart Failure. Hansen AK; Gejl M; Bouchelouche K; Tolbod LP; Gormsen LC Clin Nucl Med; 2016 Oct; 41(10):e428-35. PubMed ID: 27488429 [TBL] [Abstract][Full Text] [Related]
2. [Effect of myocardial viability and coronary revascularization on clinical outcome and prognosis: a follow-up study of 161 patients with coronary heart disease]. vom Dahl J; Altehoefer C; Büchin P; Sheehan FH; Schwarz ER; Koch KC; Schulz G; Uebis R; Schöndube F; Messmer BJ; Büll U; Hanrath P Z Kardiol; 1996 Nov; 85(11):868-81. PubMed ID: 9064949 [TBL] [Abstract][Full Text] [Related]
3. Clinical use of cardiac 18 F-FDG viability PET: a retrospective study of 44 patients undergoing post-test revascularization. Luong TV; Ebbehoj A; Kjaerulff MLG; Nielsen R; Nielsen PH; Christiansen EH; Tolbod LP; Søndergaard E; Gormsen LC Int J Cardiovasc Imaging; 2022 Nov; 38(11):2447-2458. PubMed ID: 36434332 [TBL] [Abstract][Full Text] [Related]
4. Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment. Santana CA; Faber TL; Soler-Peter M; Sanyal R; Esteves FP; Ornelas M; Folks RD; Verdes L; Santana LF; Candell-Riera J; Garcia EV Nucl Med Commun; 2008 Nov; 29(11):970-81. PubMed ID: 18836375 [TBL] [Abstract][Full Text] [Related]
5. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Ling LF; Marwick TH; Flores DR; Jaber WA; Brunken RC; Cerqueira MD; Hachamovitch R Circ Cardiovasc Imaging; 2013 May; 6(3):363-72. PubMed ID: 23595888 [TBL] [Abstract][Full Text] [Related]
6. The utility of Moody JB; Hiller KM; Lee BC; Poitrasson-Rivière A; Corbett JR; Weinberg RL; Murthy VL; Ficaro EP J Nucl Cardiol; 2019 Apr; 26(2):374-386. PubMed ID: 30809755 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease. Mc Ardle B; Shukla T; Nichol G; deKemp RA; Bernick J; Guo A; Lim SP; Davies RA; Haddad H; Duchesne L; Hendry P; Masters R; Ross H; Freeman M; Gulenchyn K; Racine N; Humen D; Benard F; Ruddy TD; Chow BJ; Mielniczuk L; DaSilva JN; Garrard L; Wells GA; Beanlands RS; Circ Cardiovasc Imaging; 2016 Sep; 9(9):. PubMed ID: 27609816 [TBL] [Abstract][Full Text] [Related]
8. Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease. Wu YW; Tadamura E; Yamamuro M; Kanao S; Marui A; Tanabara K; Komeda M; Togashi K J Nucl Med; 2007 Jul; 48(7):1096-103. PubMed ID: 17607039 [TBL] [Abstract][Full Text] [Related]
9. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. Bax JJ; Visser FC; Elhendy A; Poldermans D; Cornel JH; van Lingen A; Boersma E; Sloof GW; Fioretti PM; Visser CA J Nucl Med; 1999 Nov; 40(11):1866-73. PubMed ID: 10565782 [TBL] [Abstract][Full Text] [Related]
10. Ischemic heart failure mortality is not predicted by cardiac insulin resistance but by diabetes per se and coronary flow reserve: A retrospective dynamic cardiac Luong TV; Pedersen MGB; Kjærulff MLBG; Madsen S; Lauritsen KM; Tolbod LP; Søndergaard E; Gormsen LC Metabolism; 2021 Oct; 123():154862. PubMed ID: 34375646 [TBL] [Abstract][Full Text] [Related]
11. [Hibernating myocardium and the 'no reflow' phenomenon: a study of absolute regional myocardial perfusion and glucose metabolism using positron emission tomography in chronic and acute heart disorders]. Maes A; Nuyts J Verh K Acad Geneeskd Belg; 1997; 59(3):133-60. PubMed ID: 9490915 [TBL] [Abstract][Full Text] [Related]
12. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. D'Egidio G; Nichol G; Williams KA; Guo A; Garrard L; deKemp R; Ruddy TD; DaSilva J; Humen D; Gulenchyn KY; Freeman M; Racine N; Benard F; Hendry P; Beanlands RS; JACC Cardiovasc Imaging; 2009 Sep; 2(9):1060-8. PubMed ID: 19761983 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET. Zhang X; Liu XJ; Wu Q; Shi R; Gao R; Liu Y; Hu S; Tian Y; Guo S; Fang W J Nucl Med; 2001 Aug; 42(8):1166-73. PubMed ID: 11483675 [TBL] [Abstract][Full Text] [Related]
14. Electromechanical properties of perfusion/metabolism mismatch: comparison of nonfluoroscopic electroanatomic mapping with 18F-FDG PET. Graf S; Gyöngyösi M; Khorsand A; Nekolla SG; Pirich C; Kletter K; Dudczak R; Glogar D; Porenta G; Sochor H J Nucl Med; 2004 Oct; 45(10):1611-8. PubMed ID: 15471823 [TBL] [Abstract][Full Text] [Related]
15. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. vom Dahl J; Altehoefer C; Sheehan FH; Buechin P; Schulz G; Schwarz ER; Koch KC; Uebis R; Messmer BJ; Buell U; Hanrath P J Nucl Med; 1997 May; 38(5):742-8. PubMed ID: 9170439 [TBL] [Abstract][Full Text] [Related]
16. Myocardial viability assessment by PET: (82)Rb defect washout does not predict the results of metabolic-perfusion mismatch. Stankewicz MA; Mansour CS; Eisner RL; Churchwell KB; Williams BR; Sigman SR; Streeter J; Patterson RE J Nucl Med; 2005 Oct; 46(10):1602-9. PubMed ID: 16204709 [TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. Abraham A; Nichol G; Williams KA; Guo A; deKemp RA; Garrard L; Davies RA; Duchesne L; Haddad H; Chow B; DaSilva J; Beanlands RS; J Nucl Med; 2010 Apr; 51(4):567-74. PubMed ID: 20237039 [TBL] [Abstract][Full Text] [Related]
18. Assessment of myocardial viability by PET. Khalaf S; Chamsi-Pasha M; Al-Mallah MH Curr Opin Cardiol; 2019 Sep; 34(5):466-472. PubMed ID: 31393420 [TBL] [Abstract][Full Text] [Related]
19. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Di Carli MF; Davidson M; Little R; Khanna S; Mody FV; Brunken RC; Czernin J; Rokhsar S; Stevenson LW; Laks H Am J Cardiol; 1994 Mar; 73(8):527-33. PubMed ID: 8147295 [TBL] [Abstract][Full Text] [Related]
20. Relationship between collateral circulation and myocardial viability of Dong W; Li J; Mi H; Song X; Jiao J; Li Q Ann Nucl Med; 2018 Apr; 32(3):197-205. PubMed ID: 29380138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]